| Literature DB >> 16318051 |
N V Edeleva, N A Osipova, E R Nemtsova, R I Iakubovskaia, L M Ivanova, V I Chissov.
Abstract
The paper summarizes the results of 10 years' experience in using the biocompatible antioxidant ceruloplasmin in cancer patients to prevent and treat life-threatening complications in critical states caused by various complications after extensive surgical interventions for malignant tumors or massive intraoperative blood loss. Hemorrhagic shock-complicated intraoperative massive blood loss is shown to exert a significant damaging effect on the redox system, which correlates with the objectified severity of a critical condition and with the degree of experienced hypoxia. The use of ceruloplasmin in cancer patients with postoperative complications or massive intraoperative blood loss contributes to the recovery of the potential of the antioxidative defense system, to the correction of oxidative stress, acute multiple organ deficiency, and endotoxemia, and to the reduction of the incidence of pyoseptic complications.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16318051
Source DB: PubMed Journal: Anesteziol Reanimatol ISSN: 0201-7563